

Table 19.29  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2007-2013

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
Lymphoid Neoplasm	178,161	70.2 ( 69.9 , 70.5 )	90.2 ( 89.5 , 90.9 )	77.8 ( 77.4 , 78.1 )	59.8 ( 59.3 , 60.3 )			
1 Hodgkin Lymphoma	14,839	86.4 ( 85.7 , 87.1 )	96.6 ( 95.5 , 97.4 )	90.0 ( 89.3 , 90.7 )	56.7 ( 53.7 , 59.7 )			
2 Non-Hodgkin lymphoma	159,174	69.1 ( 68.8 , 69.4 )	88.5 ( 87.7 , 89.3 )	76.2 ( 75.8 , 76.6 )	60.4 ( 59.9 , 61.0 )			
2(a) Non-Hodgkin lymphoma, B-cell	147,279	69.4 ( 69.1 , 69.8 )	89.2 ( 88.2 , 90.0 )	76.9 ( 76.5 , 77.3 )	61.0 ( 60.4 , 61.5 )			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	8,130	68.6 ( 67.4 , 69.7 )	88.7 ( 87.6 , 89.6 )	39.3 ( 36.9 , 41.7 )	18.0 ( 14.5 , 21.8 )			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	131,742	69.6 ( 69.3 , 70.0 )	91.3 ( 89.4 , 93.0 )	78.4 ( 78.0 , 78.8 )	61.4 ( 60.8 , 61.9 )			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	31,636	79.1 ( 78.4 , 79.8 )	- ( - , - )	87.1 ( 86.3 , 87.9 )	73.6 ( 72.4 , 74.6 )			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	27,738	82.1 ( 81.3 , 82.8 )	- ( - , - )	90.0 ( 89.1 , 90.8 )	76.7 ( 75.5 , 77.9 )			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	90	51.2 ( 37.2 , 63.6 )	- ( - , - )	63.4 ( 42.0 , 78.7 )	41.7 ( 23.8 , 58.7 )			
2(a) 2.1.3. Mantle-cell lymphoma	3,808	57.9 ( 55.7 , 60.1 )	- ( - , - )	68.8 ( 65.8 , 71.5 )	49.1 ( 45.8 , 52.3 )			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	2,893	81.6 ( 79.0 , 83.8 )	- ( - , - )	88.8 ( 85.8 , 91.2 )	77.2 ( 73.5 , 80.5 )			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,314	77.4 ( 73.5 , 80.8 )	- ( - , - )	84.1 ( 79.1 , 87.9 )	73.4 ( 67.8 , 78.2 )			
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,579	85.1 ( 81.6 , 88.0 )	- ( - , - )	92.7 ( 88.7 , 95.3 )	80.4 ( 75.2 , 84.6 )			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	34,173	62.3 ( 61.6 , 62.9 )	89.6 ( 86.2 , 92.2 )	71.9 ( 71.1 , 72.7 )	52.4 ( 51.3 , 53.4 )			
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	33,713	62.1 ( 61.4 , 62.8 )	90.1 ( 86.6 , 92.6 )	71.8 ( 70.9 , 72.6 )	52.4 ( 51.3 , 53.4 )			
2(a) 2.3.2. Intravascular large B-cell lymphoma	61	50.1 ( 34.4 , 63.9 )	- ( - , - )	51.0 ( 31.9 , 67.2 )	49.5 ( 25.4 , 69.7 )			
2(a) 2.3.3. Primary effusion lymphoma	51	22.0 ( 9.2 , 38.2 )	- ( - , - )	19.6 ( 6.7 , 37.4 )	- ( - , - )			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	348	87.6 ( 82.5 , 91.2 )	- ( - , - )	89.3 ( 84.1 , 92.8 )	- ( - , - )			
2(a) 2.4. Burkitt lymphoma/leukemia	2,244	62.5 ( 60.2 , 64.6 )	91.2 ( 88.1 , 93.5 )	58.5 ( 55.6 , 61.4 )	39.9 ( 34.4 , 45.3 )			
2(a) 2.5. Marginal-zone lymphoma (MZL)	9,606	90.0 ( 88.8 , 91.0 )	98.6 ( 90.2 , 99.8 )	93.5 ( 92.3 , 94.5 )	86.5 ( 84.4 , 88.4 )			
2(a) 2.5.1. Splenic MZL	841	84.4 ( 79.6 , 88.1 )	- ( - , - )	84.5 ( 78.6 , 88.8 )	84.1 ( 76.3 , 89.5 )			
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	5,861	94.5 ( 93.0 , 95.7 )	97.8 ( 85.5 , 99.7 )	96.2 ( 94.8 , 97.2 )	92.6 ( 89.6 , 94.7 )			
2(a) 2.5.3. Nodal MZL	2,904	82.6 ( 80.1 , 84.7 )	- ( - , - )	89.8 ( 87.2 , 91.9 )	76.7 ( 72.9 , 80.1 )			
2(a) 2.6. Follicular lymphoma	17,820	87.7 ( 86.9 , 88.4 )	97.4 ( 81.9 , 99.7 )	92.2 ( 91.5 , 92.9 )	81.5 ( 79.9 , 83.0 )			
2(a) 2.7. Hairy-cell leukemia	1,562	93.5 ( 90.8 , 95.4 )	- ( - , - )	96.7 ( 94.5 , 98.1 )	85.1 ( 77.2 , 90.5 )			
2(a) 2.8. Plasma cell neoplasms	31,780	49.5 ( 48.7 , 50.2 )	- ( - , - )	62.2 ( 61.1 , 63.3 )	39.5 ( 38.5 , 40.6 )			
2(a) 2.8.1. Plasmacytoma	1,954	68.2 ( 65.2 , 71.0 )	- ( - , - )	78.2 ( 74.8 , 81.3 )	54.8 ( 49.6 , 59.7 )			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	29,826	48.3 ( 47.5 , 49.0 )	- ( - , - )	60.8 ( 59.7 , 61.9 )	38.8 ( 37.7 , 39.8 )			
2(a) 2.9. Heavy chain disease	28	70.4 ( 43.2 , 86.3 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	7,407	67.3 ( 65.7 , 68.9 )	92.1 ( 83.1 , 96.4 )	76.2 ( 74.1 , 78.1 )	61.2 ( 58.9 , 63.5 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.29 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2007-2013

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
2(b) Non-Hodgkin lymphoma, T-cell	10,802	65.4 ( 64.3 , 66.5 )	86.2 ( 84.0 , 88.2 )	69.4 ( 68.1 , 70.8 )	50.9 ( 48.5 , 53.2 )				
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	404	67.0 ( 62.1 , 71.5 )	89.6 ( 84.4 , 93.2 )	50.0 ( 42.2 , 57.3 )	6.4 ( 0.6 , 23.3 )				
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	10,359	65.4 ( 64.3 , 66.6 )	85.4 ( 82.9 , 87.7 )	70.2 ( 68.8 , 71.5 )	51.4 ( 49.0 , 53.7 )				
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,605	90.3 ( 88.2 , 92.1 )	96.6 ( 76.7 , 99.6 )	92.8 ( 90.7 , 94.4 )	84.7 ( 79.2 , 88.8 )				
2(b) 2.1.1. Mycosis fungoides	2,525	91.9 ( 89.8 , 93.6 )	96.6 ( 76.7 , 99.6 )	93.8 ( 91.7 , 95.3 )	87.5 ( 81.7 , 91.5 )				
2(b) 2.1.2. Sezary syndrome	80	37.6 ( 22.5 , 52.7 )	- ( - , - )	40.6 ( 19.5 , 60.8 )	34.5 ( 14.2 , 56.0 )				
2(b) 2.2. Peripheral T-cell lymphoma	5,693	57.5 ( 55.9 , 59.1 )	83.5 ( 78.0 , 87.7 )	66.0 ( 64.0 , 67.8 )	42.5 ( 39.7 , 45.3 )				
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	1,993	38.5 ( 35.8 , 41.1 )	60.3 ( 42.7 , 74.0 )	48.5 ( 44.9 , 51.9 )	25.8 ( 21.9 , 29.8 )				
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	749	40.7 ( 36.4 , 45.0 )	- ( - , - )	52.1 ( 45.6 , 58.1 )	31.7 ( 25.9 , 37.6 )				
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	74	89.2 ( 76.1 , 95.4 )	- ( - , - )	86.3 ( 70.5 , 94.0 )	- ( - , - )				
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,122	62.1 ( 58.7 , 65.4 )	86.9 ( 80.1 , 91.5 )	67.6 ( 63.5 , 71.3 )	34.0 ( 26.4 , 41.7 )				
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	53	20.8 ( 9.2 , 35.6 )	- ( - , - )	18.1 ( 5.8 , 35.8 )	- ( - , - )				
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	64	10.7 ( 3.5 , 22.5 )	- ( - , - )	- ( - , - )	15.9 ( 4.3 , 34.1 )				
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	1,126	84.4 ( 81.1 , 87.2 )	96.3 ( 76.3 , 99.5 )	88.2 ( 84.6 , 90.9 )	77.5 ( 71.2 , 82.5 )				
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	512	89.3 ( 84.1 , 92.8 )	- ( - , - )	94.6 ( 90.0 , 97.1 )	78.7 ( 65.5 , 87.3 )				
2(b) 2.3. Adult T-cell leukemia/lymphoma	1,359	63.6 ( 60.5 , 66.5 )	85.2 ( 81.9 , 87.9 )	46.1 ( 40.7 , 51.4 )	18.6 ( 10.6 , 28.4 )				
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	458	43.6 ( 38.1 , 48.9 )	- ( - , - )	44.4 ( 38.3 , 50.4 )	37.5 ( 25.7 , 49.2 )				
2(b) 2.5. T-cell large granular lymphocytic leukemia	78	70.4 ( 56.5 , 80.6 )	- ( - , - )	78.9 ( 61.9 , 89.0 )	57.0 ( 34.4 , 74.4 )				
2(b) 2.6. Prolymphocytic leukemia, T-cell	166	16.2 ( 9.1 , 25.1 )	- ( - , - )	21.0 ( 11.8 , 31.9 )	9.2 ( 1.8 , 24.1 )				
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	39	42.7 ( 26.6 , 57.8 )	- ( - , - )	- ( - , - )	- ( - , - )				
2(c) Non-Hodgkin lymphoma, unknown lineage	1,093	59.9 ( 56.5 , 63.1 )	86.3 ( 81.2 , 90.1 )	58.3 ( 52.8 , 63.3 )	45.8 ( 40.3 , 51.2 )				
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	445	64.5 ( 59.7 , 69.0 )	86.4 ( 81.3 , 90.2 )	44.7 ( 35.0 , 53.8 )	22.9 ( 13.5 , 33.9 )				
2(c) 2. Prolymphocytic leukemia, unknown lineage	39	50.3 ( 33.2 , 65.2 )	- ( - , - )	- ( - , - )	41.5 ( 22.7 , 59.4 )				
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	609	57.0 ( 52.2 , 61.5 )	- ( - , - )	64.5 ( 57.8 , 70.4 )	50.8 ( 44.3 , 56.9 )				
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	8,979	68.4 ( 67.3 , 69.5 )	88.6 ( 87.6 , 89.6 )	40.6 ( 38.4 , 42.7 )	18.3 ( 15.1 , 21.8 )				
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	148	72.5 ( 62.3 , 80.4 )	- ( - , - )	81.8 ( 70.4 , 89.2 )	52.5 ( 32.0 , 69.5 )				
4 Lymphoid neoplasm, NOS <sup>e</sup>	4,000	50.2 ( 48.3 , 52.2 )	85.2 ( 75.4 , 91.3 )	63.5 ( 60.6 , 66.1 )	40.1 ( 37.3 , 42.8 )				

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

<sup>e</sup> - Statistic not displayed due to less than 25 cases.